Companies: 10,795·Total market cap: $144.5T
Evaxion Biotech A/S

Evaxion Biotech A/S

EVAXNASDAQHealthcare● Active
$3.76
+$0.03(+0.80%)
Market Cap$23750311
P/E Ratio
52W High$12.15
52W Low$2.07
Overview
Foreign Private Issuer · Files 20-F / 6-K

Evaxion Biotech A/S (EVAX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001828253 · EVAX · NASDAQ · as of Jun 9, 2026

Filing snapshot

346
Total Filings
6-K
Latest Form
2026-05-12
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001828253 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001171843-26-001346
Primary Document
evax20251231_20f.htm
Source: data.sec.gov · CIK 0001828253 · Accession 0001171843-26-001346

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2026-05-12
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-12
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-07
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-04
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-27
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-04-24
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-22
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-17
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-17
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-16
View
3/AInitial Statement of Beneficial Ownership (Amended)
OWNERSHIP DOCUMENT
2026-04-10
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-07
View
3/AInitial Statement of Beneficial Ownership (Amended)
OWNERSHIP DOCUMENT
2026-04-02
View
3/AInitial Statement of Beneficial Ownership (Amended)
OWNERSHIP DOCUMENT
2026-04-01
View
3/AInitial Statement of Beneficial Ownership (Amended)
OWNERSHIP DOCUMENT
2026-03-31
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-03-30
View
Showing 1–15 of 346 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001828253  |  Exchange: NASDAQ · Healthcare

Evaxion Biotech A/S (NASDAQ: EVAX) has submitted 346 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001828253, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Evaxion Biotech A/S's most comprehensive regulatory disclosure. The most recent Evaxion Biotech A/S 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical EVAX 10-K annual reports are available from 2020 through 2026.

Investors researching Evaxion Biotech A/S SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

EVAX SEC Filings · 8 questions

Evaxion Biotech A/S (EVAX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 346 filings and access original documents at no cost. Evaxion Biotech A/S's CIK is 0001828253.

EVAX SEC filingsEvaxion Biotech A/S SEC documentsfind EVAX 10-K